Interleukin-6 serum levels in metastatic breast cancer and non-metastatic breast cancer

Introduction: This study has investigated the correlation between IL-6 serum levels with distant metastatic breast cancer incidence. Methods: We recruited female breast cancer patients at Dr. Soetomo General Hospital from March until May 2022. The sample was divided into 2 groups that consist Metastatic Breast Cancer (MBC) and non-MBC. After the stage, the IL-6 serum levels were measured. The study design was an observational analytic study, comparative analytics by comparing IL-6 serums levels in both groups: MBC and non-MBC. Results: Sixty patients, with the Non-Specific type being the common histopathology type found in this study (85%). We found 29 patients with metastases and 31 patients without metastases. Overall analyses identify Patient with high IL-6 serum levels had a 2.54 times higher chance of having a metastasis than patients with low IL-6 serum levels (95% CI = 1.39-4.63). Conclusions: Subjects with IL-6 serum levels >15.495 pg/mL had a higher risk for incidence of metastatic. The IL-6 serum levels may be a potential biomarker to predict metastases in breast cancer patients.